MEDI-1191 by Moderna for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MEDI-1191 overview

MEDI-1191 (mRNA-2905) is under development for the treatment of solid tumors.  It is administered through intratumoral injection. The therapeutic candidate comprises of an mRNA encapsulating human IL-12B (p40) and IL-12A (p35) subunits using LNP technology. It acts by targeting interleukin-12 protein. It was developed based on messenger RNA expression and N2GL formulation platform. The drug candidate was a new molecule entity (NME).

It was also under development for the treatment of solid tumor, pancreatic cancer, breast cancer, sarcomas, anal cancer, neuroendocrine cancer, unknown primary cancer, head and neck cancer squamous cell carcinoma, colorectal cancer, non-small cell lung cancer, gastric cancer, unspecified cancer and melanoma.

Moderna overview

Moderna is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of MEDI-1191’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.